Table 3 Univariate Analysis of Overall Survival
Variable | No. | Survival time, median (ranqe), mo | p value |
|---|---|---|---|
Age, median (range), y | |||
<65 | 30 | 26 (17.2–34.8) | 0.962 |
≥65 | 31 | 26 (8.3–43.8) | |
Sex | |||
Male | 30 | 32 (12.9–51.1) | 0.489 |
Female | 31 | 24 (13.8–34.2) | |
No. of metastatic/recurrent lesions | |||
1–2 | 54 | 32 (18.0–46.0) | 0.031 |
3–5 | 7 | 18 (10.3–25.7) | |
Oligostatus | |||
Oligometastases (primary active) | 11 | 18 (14.8–21.2) | 0.001 |
Oligo-recurrence (primary controlled) | 50 | 41 (27.8–54.2) | |
Histological status | |||
Squamous cell carcinoma | 6 | 32 (18.4–45.6) | 0.233 |
Adenocarcinoma | 48 | 19 (7.0–31.0) | |
Others | 7 | 19 (8.7–29.3) | |
KPS score | |||
70–80 | 5 | 24 (9.9–38.1) | 0.169 |
90–100 | 56 | 32 (19.2–44.8) | |
Interval to brain recurrence, months | |||
<12 | 29 | 19 (14.9–23.2) | 0.081 |
≥12 | 32 | 41 (34.6–47.4) | |
No. of brain metastases | |||
Single | 42 | 26 (11.3–40.7) | 0.817 |
2–4 | 19 | 26 (16.5–35.5) | |
RPA | |||
Class I | 26 | 30 (8.6–51.4) | 0.319 |
Class II | 35 | 25 (10.6–39.4) | |
GPA | |||
Intermediate Prognosis Group (1.5–3.0) | 50 | 26 (16.9–35.1) | 0.577 |
Favorable Prognosis Group (3.5–4.0) | 11 | 25 (0.0–51.8) | |
Neurologic function a | |||
Grade 0–1 | 40 | 26 (11.1–40.9) | 0.945 |
Grade 2–4 | 21 | 26 (16.5–35.5) | |
Treatment method for brain tumor | |||
SRS | 45 | 26 (17.3–34.7) | 0.792 |
SRT | 16 | 25 (1.7–48.3) | |
WBRT | |||
Yes | 9 | 25 (11.1–38.9) | 0.774 |
No | 52 | 26 (12.0–40.0) | |
Thoracic stage b | |||
I–II | 27 | 25 (16.8–33.2) | 0.199 |
III | 34 | 37 (20.1–53.9) | |
Treatment method for thoracic lesions | |||
Surgery | 43 | 30 (20.2–39.8) | 0.94 |
Radiation therapy | 18 | 25 (3.2–46.8) | |
Chemotherapy | |||
Yes | 19 | 26 (24.1–27.9) | 0.975 |
No | 42 | 30 (9.0–51.0) | |